Fri, Mar 6, 2015, 8:23 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Nektar Therapeutics (NKTR) Message Board

  • kklausbeckerman kklausbeckerman Nov 23, 2012 8:18 PM Flag

    MAP Gets FDA Approval,

    By Mark Lawson | More Articles
    November 23, 2012
    In a Wednesday press release, MAP Pharmaceuticals (NASDAQ:MAPP) reported that the FDA has accepted for filing its New Drug Application resubmission for the Lexadex orally inhaled migraine medication for the potential acute treatment of migraine in adults, classifying the resubmission as a complete Class 2 response to the its March 26th action letter. The agency has set a target date of April 15th under the Prescription Drug User Fee Act. Shares gained more than 20 percent on Friday’s short trading day

 
NKTR
13.02-0.28(-2.11%)Mar 6 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.